Unknown

Dataset Information

0

Impact of the Introduction of Rotavirus Vaccine on Hospital Admissions for Diarrhea Among Children in Kenya: A Controlled Interrupted Time-Series Analysis.


ABSTRACT:

Background

Monovalent rotavirus vaccine, Rotarix (GlaxoSmithKline), was introduced in Kenya in July 2014 and is recommended to infants as oral doses at ages 6 and 10 weeks. A multisite study was established in 2 population-based surveillance sites to evaluate vaccine impact on the incidence of rotavirus-associated hospitalizations (RVHs).

Methods

Hospital-based surveillance was conducted from January 2010 to June 2017 for acute diarrhea hospitalizations among children aged <5 years in 2 health facilities in Kenya. A controlled interrupted time-series analysis was undertaken to compare RVH pre- and post-vaccine introduction using rotavirus-negative cases as a control series. The change in incidence post-vaccine introduction was estimated from a negative binomial model that adjusted for secular trend, seasonality, and multiple health worker industrial actions (strikes).

Results

Between January 2010 and June 2017 there were 1513 and 1652 diarrhea hospitalizations in Kilifi and Siaya; among those tested for rotavirus, 28% (315/1142) and 23% (197/877) were positive, respectively. There was a 57% (95% confidence interval [CI], 8-80%) reduction in RVHs observed in the first year post-vaccine introduction in Kilifi and a 59% (95% CI, 20-79%) reduction in Siaya. In the second year, RVHs decreased further at both sites, 80% (95% CI, 46-93%) reduction in Kilifi and 82% reduction in Siaya (95% CI. 61-92%); this reduction was sustained at both sites into the third year.

Conclusions

A substantial reduction in RVHs and all-cause diarrhea was observed in 2 demographic surveillance sites in Kenya within 3 years of vaccine introduction.

SUBMITTER: Otieno GP 

PROVIDER: S-EPMC7245159 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of the Introduction of Rotavirus Vaccine on Hospital Admissions for Diarrhea Among Children in Kenya: A Controlled Interrupted Time-Series Analysis.

Otieno Grieven P GP   Bottomley Christian C   Khagayi Sammy S   Adetifa Ifedayo I   Ngama Mwanajuma M   Omore Richard R   Ogwel Billy B   Owor Betty E BE   Bigogo Godfrey G   Ochieng John B JB   Onyango Clayton C   Juma Jane J   Mwenda Jason J   Tabu Collins C   Tate Jacqueline E JE   Addo Yaw Y   Britton Tuck T   Parashar Umesh D UD   Breiman Robert F RF   Verani Jennifer R JR   Nokes D James DJ  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20200501 11


<h4>Background</h4>Monovalent rotavirus vaccine, Rotarix (GlaxoSmithKline), was introduced in Kenya in July 2014 and is recommended to infants as oral doses at ages 6 and 10 weeks. A multisite study was established in 2 population-based surveillance sites to evaluate vaccine impact on the incidence of rotavirus-associated hospitalizations (RVHs).<h4>Methods</h4>Hospital-based surveillance was conducted from January 2010 to June 2017 for acute diarrhea hospitalizations among children aged <5 year  ...[more]

Similar Datasets

| S-EPMC11470638 | biostudies-literature
| S-EPMC8600916 | biostudies-literature
| S-EPMC9121886 | biostudies-literature
| S-EPMC6303621 | biostudies-literature
| S-EPMC3654159 | biostudies-literature
| S-EPMC7977076 | biostudies-literature
| S-EPMC3823974 | biostudies-literature
| S-EPMC10190042 | biostudies-literature
| S-EPMC11232189 | biostudies-literature
| S-EPMC8758080 | biostudies-literature